Itraconazole, a potent inhibitor of P-glycoprotein, moderately increases plasma concentrations of oral morphine

Acta Anaesthesiologica Scandinavica

Volumn 52, Issue 10, 2008, Pages 1319-1326

  Heiskanen, T ^a,c   Backman, J T ^b   Neuvonen, M ^b   Kontinen, V K ^a   Neuvonen, P J ^b   Kalso, E ^a,b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c Department of Anaesthesiology and Intensive Care Medicine   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN P; ITRACONAZOLE; MORPHINE; MORPHINE 3 GLUCURONIDE; MORPHINE 6 GLUCURONIDE; PLACEBO;

AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG PENETRATION; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; VISUAL ANALOG SCALE;

ADMINISTRATION, ORAL; ADULT; ANALGESICS, OPIOID; ANTIFUNGAL AGENTS; AREA UNDER CURVE; CENTRAL NERVOUS SYSTEM STIMULANTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; HUMANS; ITRACONAZOLE; MALE; MORPHINE; MORPHINE DERIVATIVES; OXYGEN; P-GLYCOPROTEIN; PAIN MEASUREMENT; RESEARCH DESIGN;

EID: 54049083396     PISSN: 00015172     EISSN: 13996576     Source Type: Journal    
DOI: 10.1111/j.1399-6576.2008.01739.x     Document Type: Article

References (38)

1. Thompson SJ, Koszdin K, Bernards CM. Opiate-induced analgesia is increased and prolonged in mice lacking P-glycoprotein. Anesthesiology 2000 92 : 1392 9.
2. Wandel C, Kim R, Wood M, Wood A. Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein. Anesthesiology 2002 96 : 913 20.
3. King M, Su W, Chang A, Zuckerman A, Pasternak GW. Transport of opioids from the brain to the periphery by P-glycoprotein: peripheral actions of central drugs. Nat Neurosci 2001 4 : 268 74.
4. Yu C, Kastin AJ, Tu H, Waters S, Pan W. TNF activates P-glycoprotein in cerebral microvascular endothelial cells. Cell Physiol Biochem 2007 20 : 853 8.
5. Letrent SP, Polli JW, Humphreys JE, Pollack GM, Brouwer KR, Brouwer KLR. P-glycoprotein-mediated transport of morphine in brain capillary endothelial cells. Biochem Pharmacol 1999 58 : 951 7.
6. Drewe J, Ball HA, Beglinger C, Peng B, Kemmler A, Schächinger H, Haefeli WE. Effect of P-glycoprotein modulation on the clinical pharmacokinetics and adverse effects of morphine. Br J Clin Pharmacol 2000 50 : 237 46.
7. Skarke C, Jarrar M, Erb K, Schmidt H, Geisslinger G, Lötsch J. Respiratory and miotic effects of morphine in healthy volunteers when P-glycoprotein is blocked by quinidine. Clin Pharmacol Ther 2003 74 : 303 11.
8. Kharasch ED, Hoffer C, Whittington D. The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. Br J Clin Pharmacol 2004 57 : 600 10.
9. Kharasch ED, Hoffer C, Whittington D, Sheffels P. Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine. Clin Pharmacol Ther 2003 74 : 543 54.
10. Wang E, Lew K, Casciano CN, Clement RP, Johnson WW. Interaction of common azole antifungals with P-glycoprotein. Antimicrob Agents Chemother 2002 46 : 260 5.
11. Stone BM. Pencil and paper tests: sensitivity to psychotropic drugs. Br J Clin Pharmacol 1984 18 : 15S 20.
12. Smith JM, Misiak H. Critical flicker frequency (CFF) and psychotropic drugs in normal human subjects: a review. Psychopharmacologia 1976 47 : 175 82.
13. Schoppe KJ. Das MLS-Gerät. Ein neuer Testapparat zur Messung feinmotorischer Leistungen. Diagnostica 1974 20 : 43 7.
14. Zheng M, McErlane KM, Ong MC. High-performance liquid chromatography-mass spectrometry analysis of morphine and morphine metabolites and its application to a pharmacokinetic study in male Sprague-Dawley rats. J Pharm Biomed Anal 1998 16 : 971 80.
15. Jalava KM, Partanen J, Neuvonen PJ. Itraconazole decreases renal clearance of digoxin. Ther Drug Monit 1997 19 : 609 13.
16. Partanen J, Jalava M, Neuvonen PJ. Itraconazole increases serum digoxin concentration. Pharmacol Toxicol 1996 79 : 274 6.
17. Shimizu M, Uno T, Sugawara K, Tateishi T. Effect of single and multiple doses of itraconazole on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. Br J Clin Pharmacol 2006 62 : 372 6.
18. Niemi M, Tornio A, Pasanen MK, Fredrikson H, Neuvonen PJ, Backman JT. Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide. Eur J Clin Pharmacol 2006 62 : 463 72.
19. Keogh JP, Kunta JR. Development, validation and utility of an in vitro technique for assessment of potential clinical drug-drug interactions involving P-glycoprotein. Eur J Pharm Sci 2006 27 : 543 54.
20. Jurima-Romet R, Crawford K, Cyr T, Inaba T. Terfenadine metabolism in human liver. In vitro inhibition by macrolide antibiotics and azole antifungals. Drug Metab Dispos 1994 22 : 849 57.
21. Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994 55 : 481 5.
22. Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994 56 : 601 7.
23. Neuvonen PJ, Kantola T, Kivistö KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998 63 : 332 41.
24. Boerner U, Abbott S, Roe RL. The metabolism of morphine and heroine in man. Drug Metab Rev 1975 4 : 39 73.
25. Sadeque AJM, Wandel C, Hauibing H, Shah S, Wood AJJ. Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pharmacol Ther 2000 68 : 231 7.
26. Kharasch ED, Hoffer C, Altuntas TG, Whittington D. Quinidine as a probe for the role of P-glycoprotein in the intestinal absorption and clinical effects of fentanyl. J Clin Pharmacol 2004 44 : 224 33.
27. Vater M, Smith G, Aherne GW, Aitkenhead AR. Pharmacokinetic and analgesic effect of slow-release oral morphine sulphate in volunteers. Br J Anaesth 1984 56 : 821 7.
28. Heiskanen T, Olkkola KT, Kalso E. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacol Ther 1998 64 : 603 11.
29. Xie R, Hammarlund-Udenaes M, de Boer AG, de Lange ECM. The role of P-glycoprotein in blood-brain barrier transport of morphine: transcortical microdialysis studies in mdr1a (-/-) and mdr1a (+/+) mice. Br J Clin Pharmacol 1999 128 : 563 8.
30. Schinkel AH, Wagenaar E, Mol CA, von Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996 97 : 2517 24.
31. Letrent SP, Pollack GM, Brouwer KR, Brouwer KLR. Effect of GF120918, a potent P-glycoprotein inhibitor, on morphine pharmacokinetics and pharmacodynamics in the rat. Pharm Res 1998 15 : 599 605.
32. Bouw MR, Gårdmark M, Hammarlund-Udenaes M. Pharmacokinetic- pharmacodynamic modelling of morphine transport across the blood-brain barrier as a cause of the antinociceptive effect delay in rats - a microdialysis study. Pharm Res 2000 17 : 1220 7.
33. Ejsing TB, Linnet K. Influence of P-glycoprotein inhibition on the distribution of the tricyclic antidepressant nortriptyline over the blood-brain barrier. Hum Psychopharmacol 2005 20 : 149 53.
34. Breedveld P, Beijnen JH, Schellens JHM. Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS anticancer drugs. TIPS 2006 27 : 17 24.
35. Heiskanen TE, Ruismäki PM, Seppälä TA, Kalso EA. Morphine or oxycodone in cancer pain? Acta Oncol 2000 39 : 941 7.
36. Klepstad P, Kaasa S, Jystad Å, Hval B, Borchgrevink PC. Immediate- or sustained-release morphine for dose finding during start of morphine to cancer patients: a randomized, double-blind trial. Pain 2003 101 : 193 8.
37. Mercadante S, Casuccio A, Fulfaro F et al. Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. J Clin Oncol 2001 19 : 2898 904.
38. Campa D, Gioia A, Tomei A, Poli P, Barale R. Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin Pharmacol Ther 2008 83 : 559 66.